SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-030684
Filing Date
2022-03-04
Accepted
2022-03-04 17:16:26
Documents
12
Period of Report
2022-03-02
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm228461d1_8k.htm   iXBRL 8-K 26621
  Complete submission text file 0001104659-22-030684.txt   202390

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA scps-20220302.xsd EX-101.SCH 3054
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE scps-20220302_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE scps-20220302_pre.xml EX-101.PRE 22609
6 EXTRACTED XBRL INSTANCE DOCUMENT tm228461d1_8k_htm.xml XML 3705
Mailing Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170 (212) 479-2513
Scopus BioPharma Inc. (Filer) CIK: 0001772028 (see all company filings)

IRS No.: 821248020 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39788 | Film No.: 22715242
SIC: 2834 Pharmaceutical Preparations